

# Giovanni Grignani

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/246539/publications.pdf>

Version: 2024-02-01

151  
papers

9,135  
citations

50244

46  
h-index

46771

89  
g-index

155  
all docs

155  
docs citations

155  
times ranked

8364  
citing authors

#	ARTICLE	IF	CITATIONS
1	Soft tissue and visceral sarcomas: ESMOâ€“EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018, 29, iv51-iv67.	0.6	641
2	Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. <i>Lancet, The</i> , 2016, 387, 1629-1637.	6.3	610
3	Gastrointestinal stromal tumours: ESMOâ€“EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018, 29, iv68-iv78.	0.6	413
4	Soft tissue and visceral sarcomas: ESMOâ€“EURACANâ€“GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-upâ†. <i>Annals of Oncology</i> , 2021, 32, 1348-1365.	0.6	381
5	Bone sarcomas: ESMOâ€“PaedCanâ€“EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018, 29, iv79-iv95.	0.6	380
6	Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-ST5 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. <i>Lancet Oncology, The</i> , 2017, 18, 812-822.	5.1	370
7	A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. <i>Annals of Oncology</i> , 2012, 23, 508-516.	0.6	296
8	Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial. <i>Lancet Oncology, The</i> , 2015, 16, 98-107.	5.1	270
9	Phase II Study of Imatinib in Advanced Chordoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 914-920.	0.8	230
10	Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARCO21): an international, multicentre, open-label, randomised phase 3 trial. <i>Lancet Oncology, The</i> , 2017, 18, 1089-1103.	5.1	214
11	Gastrointestinal stromal tumours: ESMOâ€“EURACANâ€“GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2022, 33, 20-33.	0.6	213
12	Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways. <i>Molecular Cancer</i> , 2009, 8, 118.	7.9	159
13	Bone sarcomas: ESMOâ€“EURACANâ€“GENTURISâ€“ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2021, 32, 1520-1536.	0.6	150
14	Sporadic desmoid-type fibromatosis: a stepwise approach to a non-metastasising neoplasmâ€“a position paper from the Italian and the French Sarcoma Group. <i>Annals of Oncology</i> , 2014, 25, 578-583.	0.6	149
15	Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSC) retrospective analysis. <i>Acta OncolÃ³gica</i> , 2017, 56, 88-92.	0.8	146
16	Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups. <i>Journal of Clinical Oncology</i> , 2020, 38, 2178-2186.	0.8	145
17	Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine. <i>Journal of Clinical Oncology</i> , 2017, 35, 3433-3439.	0.8	126
18	The role of surgery in the multimodal treatment of primary gastric non-Hodgkin's lymphomas a report of 76 cases and review of the literature. <i>Cancer</i> , 1990, 65, 2528-2536.	2.0	120

#	ARTICLE	IF	CITATIONS
19	Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 134-144.	5.1	97
20	The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 Upregulation in Osteosarcoma Preclinical Models. <i>Clinical Cancer Research</i> , 2013, 19, 2117-2131.	3.2	96
21	Treatment of Extraspinal Painful Bone Metastases with Percutaneous Cementoplasty: A Prospective Study of 50 Patients. <i>CardioVascular and Interventional Radiology</i> , 2008, 31, 1165-1173.	0.9	93
22	Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS): long-term follow-up of a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group. <i>Annals of Oncology</i> , 2016, 27, 2283-2288.	0.6	90
23	Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. <i>Cancer</i> , 2020, 126, 2637-2647.	2.0	86
24	Tumor response assessment by modified Choi criteria in localized high-risk soft tissue sarcoma treated with chemotherapy. <i>Cancer</i> , 2012, 118, 5857-5866.	2.0	85
25	Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib/II trial. , 2020, 8, e001561.		85
26	EURO-B.O.S.S.: A European study on chemotherapy in bone-sarcoma patients aged over 40: Outcome in primary high-grade osteosarcoma. <i>Tumori</i> , 2018, 104, 30-36.	0.6	84
27	Involvement of chemokine receptor 4/stromal cell-derived factor 1 system during osteosarcoma tumor progression. <i>Clinical Cancer Research</i> , 2005, 11, 490-7.	3.2	83
28	Effective Activity of Cytokine-Induced Killer Cells against Autologous Metastatic Melanoma Including Cells with Stemness Features. <i>Clinical Cancer Research</i> , 2013, 19, 4347-4358.	3.2	81
29	Primary metastatic Ewing's family tumors: results of the Italian Sarcoma Group and Scandinavian Sarcoma Group ISG/SSC IV Study including myeloablative chemotherapy and total-lung irradiation. <i>Annals of Oncology</i> , 2012, 23, 2970-2976.	0.6	80
30	Preoperative chemo-radiation therapy for localised retroperitoneal sarcoma: A phase II study from the Italian Sarcoma Group. <i>European Journal of Cancer</i> , 2014, 50, 784-792.	1.3	80
31	Predicting Survival in Patients Undergoing Resection for Locally Recurrent Retroperitoneal Sarcoma: A Study and Novel Nomogram from TARPSWG. <i>Clinical Cancer Research</i> , 2019, 25, 2664-2671.	3.2	80
32	Gemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of bone. <i>BMC Cancer</i> , 2016, 16, 280.	1.1	71
33	Quality of surgery and neoadjuvant combined therapy in the ISG-GEIS trial on soft tissue sarcomas of limbs and trunk wall. <i>Annals of Oncology</i> , 2013, 24, 817-823.	0.6	69
34	Cytokine-Induced Killer Cells Eradicate Bone and Soft-Tissue Sarcomas. <i>Cancer Research</i> , 2014, 74, 119-129.	0.4	67
35	Extraskeletal osteosarcoma: A European Musculoskeletal Oncology Society study on 266 patients. <i>European Journal of Cancer</i> , 2017, 74, 9-16.	1.3	67
36	Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts. <i>ESMO Open</i> , 2021, 6, 100170.	2.0	65

#	ARTICLE	IF	CITATIONS
37	A prognostic index for multiple myeloma. <i>British Journal of Cancer</i> , 1996, 73, 1101-1107.	2.9	64
38	Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma. <i>JAMA Oncology</i> , 2018, 4, e180219.	3.4	63
39	Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group. <i>Lancet Oncology</i> , The, 2018, 19, 1360-1371.	5.1	61
40	Pazopanib for treatment of advanced extraskeletal myxoid chondrosarcoma: a multicentre, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1252-1262.	5.1	57
41	Efficacy and safety of avelumab treatment in patients with metastatic Merkel cell carcinoma: experience from a global expanded access program. , 2020, 8, e000313.		54
42	Genome-Wide Analysis Identifies MEN1 and MAX Mutations and a Neuroendocrine-Like Molecular Heterogeneity in Quadruple WT GIST. <i>Molecular Cancer Research</i> , 2017, 15, 553-562.	1.5	53
43	Pazopanib for treatment of typical solitary fibrous tumours: a multicentre, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 456-466.	5.1	51
44	Phase 2 trial of two courses of cyclophosphamide and etoposide for relapsed high-risk osteosarcoma patients. <i>Cancer</i> , 2009, 115, 2980-2987.	2.0	50
45	Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour. <i>European Journal of Cancer</i> , 2014, 50, 3021-3028.	1.3	50
46	Post-Transplant Cyclophosphamide and Tacrolimus/Mycophenolate Mofetil Combination Prevents Graft-versus-Host Disease in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 459-466.	2.0	50
47	Next generation immune-checkpoints for cancer therapy. <i>Journal of Thoracic Disease</i> , 2018, 10, S1581-S1601.	0.6	50
48	PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models. <i>Molecular Cancer</i> , 2017, 16, 86.	7.9	49
49	High-risk soft tissue sarcomas treated with perioperative chemotherapy: Improving prognostic classification in a randomised clinical trial. <i>European Journal of Cancer</i> , 2018, 93, 28-36.	1.3	49
50	Percutaneous Vertebroplasty in Multiple Myeloma: Prospective Long-Term Follow-Up in 106 Consecutive Patients. <i>CardioVascular and Interventional Radiology</i> , 2012, 35, 139-145.	0.9	47
51	Allogeneic nonmyeloablative hematopoietic cell transplantation in metastatic colon cancer: tumor-specific T cells directed to a tumor-associated antigen are generated in vivo during GVHD. <i>Blood</i> , 2006, 107, 3795-3803.	0.6	46
52	Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: A Sarculator-based risk stratification analysis of the ISG/STS 1001 randomized trial. <i>Cancer</i> , 2022, 128, 85-93.	2.0	46
53	A phase 2 trial of imatinib mesylate in patients with recurrent nonresectable chondrosarcomas expressing platelet-derived growth factor receptor $\alpha$ or $\beta$ . <i>Cancer</i> , 2011, 117, 826-831.	2.0	42
54	Irinotecan and temozolomide in recurrent Ewing sarcoma: an analysis in 51 adult and pediatric patients. <i>Acta Oncologica</i> , 2018, 57, 958-964.	0.8	41

#	ARTICLE	IF	CITATIONS
55	High dose chemotherapy with autologous hematopoietic stem cell support for solid tumors other than breast cancer in adults. <i>Annals of Oncology</i> , 2006, 17, 1479-1488.	0.6	39
56	Complete Resolution of Life-Threatening Bleomycin-Induced Pneumonitis After Treatment With Imatinib Mesylate in a Patient With Hodgkin's Lymphoma: Hope for Severe Chemotherapy-Induced Toxicity?. <i>Journal of Clinical Oncology</i> , 2011, 29, e691-e693.	0.8	38
57	CD44v6 as innovative sarcoma target for CAR-redirected CIK cells. <i>Oncolmmunology</i> , 2018, 7, e1423167.	2.1	38
58	Next-Generation Sequencing Approaches for the Identification of Pathognomonic Fusion Transcripts in Sarcomas: The Experience of the Italian ACC Sarcoma Working Group. <i>Frontiers in Oncology</i> , 2020, 10, 489.	1.3	38
59	Cytokine-Induced Killer Cells Kill Chemo-surviving Melanoma Cancer Stem Cells. <i>Clinical Cancer Research</i> , 2017, 23, 2277-2288.	3.2	34
60	Cabozantinib Affects Osteosarcoma Growth Through A Direct Effect On Tumor Cells and Modifications In Bone Microenvironment. <i>Scientific Reports</i> , 2018, 8, 4177.	1.6	34
61	Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib. <i>British Journal of Cancer</i> , 2017, 117, 1278-1285.	2.9	33
62	Assessment of Safety and Efficacy of Combined Trabectedin and Low-Dose Radiotherapy for Patients With Metastatic Soft-Tissue Sarcomas. <i>JAMA Oncology</i> , 2020, 6, 535.	3.4	33
63	Clinical Use of AMD3100 to Mobilize CD34+ Cells in Patients Affected by Non-Hodgkin's Lymphoma or Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2005, 23, 3871-3872.	0.8	30
64	Defining the role of neoadjuvant systemic therapy in high-risk retroperitoneal sarcoma: A multi-institutional study from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group. <i>Cancer</i> , 2021, 127, 729-738.	2.0	30
65	Treatment patterns and clinical outcomes with pazopanib in patients with advanced soft tissue sarcomas in a compassionate use setting: results of the SPIRE study. <i>Acta Oncologica</i> , 2017, 56, 1769-1775.	0.8	29
66	The sacral chordoma margin. <i>European Journal of Surgical Oncology</i> , 2020, 46, 1415-1422.	0.5	29
67	Impact of a risk-based follow-up in patients affected by gastrointestinal stromal tumour. <i>European Journal of Cancer</i> , 2017, 78, 122-132.	1.3	28
68	Pancreaticoduodenectomy in the surgical management of primary retroperitoneal sarcoma. <i>European Journal of Surgical Oncology</i> , 2018, 44, 810-815.	0.5	28
69	Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591879462.	1.4	27
70	The Activity of Chemotherapy in Inflammatory Myofibroblastic Tumors: A Multicenter, European Retrospective Case Series Analysis. <i>Oncologist</i> , 2020, 25, e1777-e1784.	1.9	27
71	Postoperative Morbidity After Resection of Recurrent Retroperitoneal Sarcoma: A Report from the Transatlantic Australasian RPS Working Group (TARPSWG). <i>Annals of Surgical Oncology</i> , 2021, 28, 2705-2714.	0.7	26
72	153Samarium-EDTMP administration followed by hematopoietic stem cell support for bone metastases in osteosarcoma patients. <i>Annals of Oncology</i> , 2012, 23, 1899-1905.	0.6	25

#	ARTICLE	IF	CITATIONS
73	Complete remission of paraneoplastic vanishing bile duct syndrome after the successful treatment of Hodgkin's lymphoma: a case report and review of the literature. BMC Research Notes, 2014, 7, 529.	0.6	24
74	The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma. BMC Cancer, 2015, 15, 374.	1.1	24
75	CSPG4-Specific CAR.CIK Lymphocytes as a Novel Therapy for the Treatment of Multiple Soft-Tissue Sarcoma Histotypes. Clinical Cancer Research, 2020, 26, 6321-6334.	3.2	24
76	Anticoagulation for Central Venous Catheters in Patients with Cancer. New England Journal of Medicine, 2014, 371, 1362-1363.	13.9	23
77	Systemic therapies in advanced epithelioid haemangioendothelioma: A retrospective international case series from the World Sarcoma Network and a review of literature. Cancer Medicine, 2021, 10, 2645-2659.	1.3	23
78	MOPP/EBV/CAD hybrid chemotherapy with or without limited radiotherapy in advanced or unfavorably presenting Hodgkin's disease: a report from the Italian Lymphoma Study Group.. Journal of Clinical Oncology, 1993, 11, 712-719.	0.8	22
79	Gain of FGF4 is a frequent event in KIT/PDGFR $\alpha$ /SDH/RAS $\pm$ WT GIST. Genes Chromosomes and Cancer, 2019, 58, 636-642.	1.5	22
80	Evaluation of the use and efficacy of (neo)adjuvant chemotherapy in angiosarcoma: a multicentre study. ESMO Open, 2020, 5, e000787.	2.0	22
81	High Dose Ifosfamide in Relapsed and Unresectable High-Grade Osteosarcoma Patients: A Retrospective Series. Cells, 2020, 9, 2389.	1.8	22
82	Randomized, open-label, multicenter, phase III study of eribulin versus dacarbazine in patients (pts) with leiomyosarcoma (LMS) and adipocytic sarcoma (ADI).. Journal of Clinical Oncology, 2015, 33, LBA10502-LBA10502.	0.8	22
83	An Acute Hepatitis Resembling Autoimmune Hepatitis Occurring During Imatinib Therapy in a Gastrointestinal Stromal Tumor Patient. American Journal of Clinical Oncology: Cancer Clinical Trials, 2009, 32, 640-641.	0.6	21
84	Ex Vivo Allogeneic Stimulation Significantly Improves Expansion of Cytokine-Induced Killer Cells Without Increasing Their Alloreactivity Across HLA Barriers. Journal of Immunotherapy, 2012, 35, 579-586.	1.2	21
85	Patterns of recurrence and survival probability after second recurrence of retroperitoneal sarcoma: A study from TARPSWG. Cancer, 2020, 126, 4917-4925.	2.0	21
86	Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practice. Therapeutic Advances in Medical Oncology, 2017, 9, 731-739.	1.4	20
87	Cytokine Induced Killer cells are effective against sarcoma cancer stem cells spared by chemotherapy and target therapy.. OncoImmunology, 2018, 7, e1465161.	2.1	20
88	Assessment of morphological CT imaging features for the prediction of risk stratification, mutations, and prognosis of gastrointestinal stromal tumors. European Radiology, 2021, 31, 8554-8564.	2.3	20
89	Pharmacokinetics, safety, and activity of trabectedin as first-line treatment in elderly patients who are affected by advanced sarcoma and are unfit to receive standard chemotherapy: A phase 2 study (TR1US) Tj ETQq1 1.0.784314rgBT /Ov	1.0	14
90	Analysis of Differentiation Changes and Outcomes at Time of First Recurrence of Retroperitoneal Liposarcoma by Transatlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG). Annals of Surgical Oncology, 2021, 28, 7854-7863.	0.7	19

#	ARTICLE	IF	CITATIONS
91	Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity. <i>Journal of Translational Medicine</i> , 2016, 14, 119.	1.8	18
92	Soft tissue sarcoma in Italy: From epidemiological data to clinical networking to improve patient care and outcomes. <i>Cancer Epidemiology</i> , 2019, 59, 258-264.	0.8	18
93	NKTR-214 + nivolumab in first-line advanced/metastatic urothelial carcinoma (mUC): Updated results from PIVOT-02.. <i>Journal of Clinical Oncology</i> , 2019, 37, 388-388.	0.8	18
94	Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study. <i>Clinical Cancer Research</i> , 2022, 28, 1672-1679.	3.2	18
95	Olaratumab: PDGFR- $\hat{1}\pm$ inhibition as a novel tool in the treatment of advanced soft tissue sarcomas. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 118, 1-6.	2.0	16
96	Targeted Deep Sequencing Uncovers Cryptic KIT Mutations in KIT/PDGFR $\alpha$ /SDH/RAS-P Wild-Type GIST. <i>Frontiers in Oncology</i> , 2020, 10, 504.	1.3	16
97	A phase II randomised (calibrated design) study on the activity of the single-agent trabectedin in metastatic or locally relapsed uterine leiomyosarcoma. <i>British Journal of Cancer</i> , 2018, 119, 565-571.	2.9	15
98	Pazopanib and Trametinib as a Synergistic Strategy against Osteosarcoma: Preclinical Activity and Molecular Insights. <i>Cancers</i> , 2020, 12, 1519.	1.7	15
99	Trabectedin for Patients with Advanced Soft Tissue Sarcoma: A Non-Interventional, Retrospective, Multicenter Study of the Italian Sarcoma Group. <i>Cancers</i> , 2021, 13, 1053.	1.7	15
100	Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 2479-2490.	0.8	15
101	In vivo characterisation of soft tissue tumours by 1.5-T proton MR spectroscopy. <i>European Radiology</i> , 2012, 22, 1131-1139.	2.3	14
102	Morbidity and Outcomes After Distal Pancreatectomy for Primary Retroperitoneal Sarcoma: An Analysis by the Trans-Atlantic Australasian Retroperitoneal Sarcoma Working Group. <i>Annals of Surgical Oncology</i> , 2021, 28, 6882-6889.	0.7	14
103	IMMUNOSARC: a collaborative Spanish (GEIS) and Italian (ISG) sarcoma groups phase I/II trial of sunitinib and nivolumab in advanced soft tissue and bone sarcoma: Results from the phase II part, bone sarcoma cohort.. <i>Journal of Clinical Oncology</i> , 2020, 38, 11522-11522.	0.8	14
104	Painful Pathologic Fracture of the Humerus: Percutaneous Osteoplasty With Bone Marrow Nails Under Hybrid Computed Tomography and Fluoroscopic Guidance. <i>Journal of Vascular and Interventional Radiology</i> , 2011, 22, 1031-1034.	0.2	13
105	Alpha $\beta$ fetoprotein elevation in NUT midline carcinoma: a case report. <i>BMC Cancer</i> , 2017, 17, 266.	1.1	13
106	Management of Locally Recurrent Retroperitoneal Sarcoma in the Adult: An Updated Consensus Approach from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group. <i>Annals of Surgical Oncology</i> , 2022, 29, 7335-7348.	0.7	13
107	Adoptive immunotherapy against sarcomas. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 517-528.	1.4	11
108	Confirmed Activity and Tolerability of Weekly Paclitaxel in the Treatment of Advanced Angiosarcoma. <i>Sarcoma</i> , 2016, 2016, 1-7.	0.7	11

#	ARTICLE	IF	CITATIONS
109	Delving into PARP inhibition from bench to bedside and back. , 2020, 206, 107446.		11
110	Trabectedin clinical cases: use according to indication in diverse clinical scenarios. Future Oncology, 2015, 11, 15-24.	1.1	10
111	Post-Transplant Cyclophosphamide and Tacrolimusâ€”Mycophenolate Mofetil Combination Governs GVHD and Immunosuppression Need, Reducing Late Toxicities in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors. Journal of Clinical Medicine, 2021, 10, 1173.	1.0	10
112	Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma. Future Oncology, 2021, 17, 2923-2939.	1.1	10
113	Standard versus personalized schedule of regorafenib in metastatic gastrointestinal stromal tumors: a retrospective, multicenter, real-world study. ESMO Open, 2021, 6, 100222.	2.0	10
114	Telomere loss in Philadelphia-negative hematopoiesis after successful treatment of chronic myeloid leukemia: Evidence for premature aging of the myeloid compartment. Mechanisms of Ageing and Development, 2012, 133, 479-488.	2.2	9
115	Analytic and Dynamic Secretary Profile of Patient-Derived Cytokine-Induced Killer Cells. Molecular Medicine, 2017, 23, 235-246.	1.9	9
116	Validation process of Toronto Extremity Salvage Score in Italian: A quality of life measure for patients with extremity bone and soft tissue tumors. Journal of Surgical Oncology, 2020, 121, 630-637.	0.8	9
117	Progressive necrotic myelopathy as a paraneoplastic syndrome: report of a case and some pathogenetic considerations. Journal of Internal Medicine, 1992, 231, 81-85.	2.7	8
118	Allogeneic Hemopoietic Stem Cell Transplantation in Solid Tumors. Transplantation Proceedings, 2005, 37, 2664-2666.	0.3	8
119	Successful treatment of gemcitabine-induced acute interstitial pneumonia with imatinib mesylate: a case report. BMC Cancer, 2016, 16, 793.	1.1	8
120	Avelumab expanded access program in metastatic Merkel cell carcinoma: Efficacy and safety findings from patients in Europe and the Middle East. International Journal of Cancer, 2021, 149, 1926-1934.	2.3	8
121	Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study. , 2022, 10, e004419.		8
122	Night sweats in Hodgkin's disease A manifestation of preceding minor febrile pulses. Cancer, 1990, 65, 2074-2077.	2.0	7
123	Response to melphalan in up-front investigational window therapy for patients with metastatic Ewingâ€™s family tumours. European Journal of Cancer, 2007, 43, 885-890.	1.3	7
124	A plea to overcome the concept of â€œstagingâ€• and related inadequacy in multiple myeloma. European Journal of Haematology, 1991, 46, 177-181.	1.1	7
125	EphA2 Expression in Bone Sarcomas: Bioinformatic Analyses and Preclinical Characterization in Patient-Derived Models of Osteosarcoma, Ewingâ€™s Sarcoma and Chondrosarcoma. Cells, 2021, 10, 2893.	1.8	7
126	<sc>CINSARC</sc> in highâ€™risk soft tissue sarcoma patients treated with neoadjuvant chemotherapy: Results from the <sc>ISGâ€™CTS</sc> 1001 study. Cancer Medicine, 2023, 12, 1350-1357.	1.3	7



#	ARTICLE	IF	CITATIONS
127	Gingival metastasis of a radiotherapy-induced breast angiosarcoma. <i>Anti-Cancer Drugs</i> , 2012, 23, 1112-1117.	0.7	6
128	Prognostic role of PD-L1 and immune-related gene expression profiles in giant cell tumors of bone. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1905-1916.	2.0	6
129	Prolonged Disease Stability With Trabectedin in a Heavily Pretreated Elderly Patient With Metastatic Leiomyosarcoma of the Thigh and Renal Failure: A Case Report and Review of the Literature. <i>Oncology Research</i> , 2012, 20, 483-490.	0.6	5
130	Preventing Venous Thromboembolism in Patients with Cancer. <i>New England Journal of Medicine</i> , 2019, 380, 2180-2181.	13.9	5
131	Avelumab treatment in Italian patients with metastatic Merkel cell carcinoma: experience from an expanded access program. <i>Journal of Translational Medicine</i> , 2021, 19, 70.	1.8	5
132	Front-Line Window Therapy with Temozolomide and Irinotecan in Patients with Primary Disseminated Multifocal Ewing Sarcoma: Results of the ISG/AIEOP EW-2 Study. <i>Cancers</i> , 2021, 13, 3046.	1.7	5
133	Weekly cisplatin with or without imatinib in advanced chordoma: A retrospective case-series analysis from the Italian Rare Cancers Network. <i>Cancer</i> , 2022, 128, 1439-1448.	2.0	5
134	Case Report: Clinical Experience With Avelumab in Patients With Metastatic Merkel Cell Carcinoma and Brain Metastases Treated in Europe. <i>Frontiers in Oncology</i> , 2021, 11, 672021.	1.3	4
135	SDHA Germline Variants in Adult Patients With SDHA-Mutant Gastrointestinal Stromal Tumor. <i>Frontiers in Oncology</i> , 2021, 11, 778461.	1.3	4
136	Systemic treatment in advanced phyllodes tumor of the breast: a multi-institutional European retrospective case-series analyses. <i>Breast Cancer Research and Treatment</i> , 2022, 192, 603-610.	1.1	4
137	Activity of cytokine-induced killer cells against bone and soft tissue sarcoma. <i>Oncolmmunology</i> , 2014, 3, e28269.	2.1	3
138	Primary mesenteric sarcomas: Collaborative experience from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG). <i>Journal of Surgical Oncology</i> , 2021, 123, 1057-1066.	0.8	3
139	Eribulin-based treatment in patients affected by sarcomas: a case series. <i>Future Oncology</i> , 2020, 16, 1-3.	1.1	3
140	Nationwide multidisciplinary consensus on the clinical management of Merkel cell carcinoma: a Delphi panel. , 2022, 10, e004742.		3
141	Response to eribulin in a patient with metastatic uterine leiomyosarcoma: a case report. <i>Future Oncology</i> , 2020, 16, 15-19.	1.1	2
142	Predictive Value of MRP-1 in Localized High-Risk Soft Tissue Sarcomas: A Translational Research Associated to ISG-STG 1001 Randomized Phase III Trial. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 2539-2552.	1.9	2
143	Maintenance therapy with oral cyclophosphamide plus celecoxib in patients with metastatic Ewing sarcoma: Results of the Italian Sarcoma Group/AIEOP EW-2 study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 10517-10517.	0.8	2
144	Front-line window therapy with cisplatin in patients with primary disseminated Ewing sarcoma: A study by the Associazione Italiana di Ematologia ed Oncologia Pediatrica and Italian Sarcoma Group. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26650.	0.8	1

#	ARTICLE	IF	CITATIONS
145	Whole Lung Irradiation after High-Dose Busulfan/Melphalan in Ewing Sarcoma with Lung Metastases: An Italian Sarcoma Group and Associazione Italiana Ematologia Oncologia Pediatrica Joint Study. <i>Cancers</i> , 2021, 13, 2789.	1.7	1
146	Tumor progression in osteosarcoma (OS): Role of the chemokine receptor CXCR4 and of its ligand stromal-cell derived factor 1 (SDF-1). <i>Journal of Clinical Oncology</i> , 2004, 22, 9021-9021.	0.8	1
147	Gastrointestinal Stromal Tumors. , 2012, , 41-60.		1
148	Immunological and Genetic Biomarkers of Sarcomas. , 2019, , 591-608.		0
149	Endoscopic submucosal dissection for chronically bleeding gastric metastasis from undifferentiated liposarcoma. <i>Digestive and Liver Disease</i> , 2020, 52, 588.	0.4	0
150	Medical Therapy in Retroperitoneal Sarcomas. <i>Updates in Surgery Series</i> , 2019, , 133-141.	0.0	0
151	PARP1 Inhibitor and Trabectedin Combination Does Not Increase Tumor Mutational Burden in Advanced Sarcomas—A Preclinical and Translational Study. <i>Cancers</i> , 2021, 13, 6295.	1.7	0